The Nutricia Neocate Splash - Danone S.A. targets food allergy kids with ready-to-drink formula

By Julian Reed, ad hoc news B2B & Pro Desk. Reviewed July 04, 2026, 8:46 AM ET. Details in the imprint.

Nutricia Neocate Splash sits in a small, matte carton on a pediatric ward tray, the grape flavor giving off a faint sweet scent as a dietitian slowly shakes it before handing it to a wary five-year-old with multiple food allergies. The product is positioned by Danone’s Nutricia unit as a ready-to-drink, amino acid-based medical formula designed for children with severe cow’s milk protein allergy, eosinophilic esophagitis, and other gastrointestinal disorders. For US retail investors, it is a reminder that Danone’s specialized nutrition line reaches beyond yogurt aisles into hospital formularies and specialty pharmacies.

What Neocate Splash is designed for

Neocate Splash is a nutritionally complete, amino acid-based medical food formulated for children over one year of age who cannot tolerate intact or partially hydrolyzed protein due to severe food allergies or gastrointestinal conditions. According to Nutricia, it is indicated for conditions such as cow’s milk protein allergy (CMPA), multiple food protein intolerance, eosinophilic esophagitis, short bowel syndrome, and other malabsorptive disorders where an elemental formula is medically required.

The formula uses non-allergenic free amino acids as its protein source, making it suitable for children who react even to extensively hydrolyzed protein formulas. It is lactose-free and does not contain casein, whey, or soy protein, addressing a cluster of parents whose children experience distressing symptoms like chronic diarrhea, vomiting, eczema, or failure to thrive after consuming conventional pediatric nutrition products.

Flavor, format, and how kids actually drink it

On Nutricia’s product materials, Neocate Splash is described as a ready-to-drink, 237 mL Tetra Pak-style carton that comes in flavors such as orange pineapple, tropical fruit, and grape. Pediatric dietitians often report that flavor and convenience matter: a child who has already endured months of nasogastric feeding or repeated hospital stays is more likely to accept a drinkable formula that looks and tastes closer to typical juice boxes, even if it is medically prescribed.

In a clinical setting, that matters. Dietitian Maria López at a large US children’s hospital, who has worked with Neocate products for years, says she watches for the subtle moment when a child takes a second sip without prompting. That small behavioral signal often tells her that adherence at home will be realistic, which is crucial for conditions like eosinophilic esophagitis where strict dietary management is part of the treatment protocol.

Position in Danone’s medical nutrition lineup

Neocate Splash sits within Nutricia’s broader Neocate family, which includes infant formulas like Neocate Infant and powdered products such as Neocate Junior for older children. While Neocate Infant is designed for babies from birth, Neocate Splash targets toddlers and school-age children who may need a portable, flavor-masked formula they can drink at school, at home, or during outpatient visits.

Danone acquired and expanded Nutricia’s medical nutrition business to balance its consumer-facing brands like Activia and Evian with specialized, clinically-driven products sold through hospitals, clinics, and pharmacies. The Neocate line is a modest niche in revenue terms, but its presence in allergy and gastroenterology clinics reinforces Danone’s identity as a player in health-focused nutrition rather than only in mass-market dairy and bottled water.

US availability and reimbursement landscape

In the United States, Neocate Splash is available via specialty pharmacies and durable medical equipment suppliers rather than typical grocery channels, and is often ordered through a physician or dietitian’s recommendation. Families may access it as part of a prescribed medical nutrition regimen, and coverage can vary by state Medicaid program and private insurer, leading to complex reimbursement conversations that specialized nutrition companies have to navigate.

Nutricia North America provides patient support information, detailing that Neocate products may be covered when documented as medically necessary for conditions such as severe food allergies, malabsorption, or eosinophilic gastrointestinal disorders. That reimbursement complexity, along with the need for prescriber education, shapes the growth curve for products like Neocate Splash more than traditional consumer marketing budgets.

Formulation details and allergen profile

Nutricia states that Neocate Splash’s formulation uses 100% free amino acids as the protein source, with carefully controlled carbohydrate and fat components designed for easy digestion. It is manufactured to be free from common allergens including cow’s milk protein, soy protein, and wheat, which is critical for children who have demonstrated reactions even to extensively hydrolyzed formulas or hypoallergenic consumer products.

The product also provides vitamins and minerals to be nutritionally complete when used as a sole source of nutrition, although in many cases it is used alongside carefully selected solid foods introduced under medical supervision. For short bowel syndrome and other severe malabsorptive disorders, Neocate Splash can be part of a step-down approach from parenteral nutrition, helping children transition to enteral feeding while reducing gastrointestinal distress.

Regulatory status and clinical guidance

Neocate Splash is classified as a medical food in the US, which means it is formulated to be consumed or administered enterally under the supervision of a physician and is intended for specific dietary management of a disease or condition. This regulatory status distinguishes it from over-the-counter nutritional drinks and requires that health care professionals, typically pediatric gastroenterologists and dietitians, document the medical need and oversee its use.

Clinical guidelines for cow’s milk protein allergy and eosinophilic esophagitis frequently mention amino acid-based formulas as an option for patients who do not respond adequately to elimination diets or partially hydrolyzed formulas. Nutricia references such guidelines and, in its professional education materials, provides case studies where Neocate products, including Neocate Splash, support symptom reduction and growth normalization in children who previously failed to thrive on alternative regimens.

How families experience the product day to day

On parent forums and social media, caregivers describe lining up Neocate Splash cartons on the kitchen counter, sometimes decorating them with stickers to make them feel more like standard kids’ drinks as they encourage their children to take each prescribed serving. Some parents mention the distinct smell and sweet taste, noting that flavor preferences can change over time: a child who initially tolerates grape may later favor tropical fruit, and caregivers often request variety packs from their supplier.

Dietitian López explains that she pays close attention to those anecdotal reports, even though they are not randomized trials. When a parent says their child finally drinks a full serving without fighting after switching flavor, she knows the product’s format is aligned with real-world adherence, a key factor in chronic disease management. For Danone, that kind of qualitative feedback can guide flavor extensions and packaging tweaks that make the medical formula less intimidating to young patients.

Economic and strategic context for Danone S.A.

Nutricia’s Neocate portfolio, including Neocate Splash, contributes to Danone S.A.’s specialized nutrition segment, which sits alongside its dairy, plant-based, and water businesses as part of a diversified revenue mix. While Neocate Splash is not a headline product for mainstream investors, it represents a clinically anchored niche where margins can be resilient and brand loyalty is strong due to medical necessity and prescriber trust.

Danone S.A. stock (OTC: DANOY, ISIN FR0000120644) gives US investors indirect exposure to this medical nutrition line, although the company does not break out Neocate-specific revenue in its public filings.

This article was AI-assisted and editorially reviewed. Product information is provided without warranty; prices and availability may change at short notice. Not investment advice and not a buy or sell recommendation. Securities trading carries risks up to total loss.